A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors.

Trial Profile

A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Pexastimogene devacirepvec (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Jennerex
  • Most Recent Events

    • 14 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Jan 2014 Planned End Date changed from 1 Sep 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
    • 15 May 2013 Research has been published in Science Translational Medicine, according to a Jennerex Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top